Neurology:表现为凸面SAH的CAA相关炎症

2019-08-29 杨中华 脑血管病及重症文献导读

非创伤性急性凸面蛛网膜下腔出血(convexity subarachnoid hemorrhage,cSAH)是脑淀粉样血管病(cerebral amyloid angiopathy,CAA)的常见表现,但是CAA-相关炎症(CAA-related inflammation,CAA-RI)者很少报道 cSAH。

非创伤性急性凸面蛛网膜下腔出血(convexity subarachnoid hemorrhage,cSAH)是脑淀粉样血管病(cerebral amyloid angiopathy,CAA)的常见表现,但是CAA-相关炎症(CAA-related inflammation,CAA-RI)者很少报道 cSAH。

89岁,女性。

表现为视幻觉、定向力障碍和烦躁1个月。

脑 MRI 显示播散性皮层表面铁质沉积,脑微出血和双侧半球不对称白质高信号。右侧顶叶也可以见到亚急性出血,伴蛛网膜下腔弥散抑制和强化。

下图 A,轴位 SWI 显示凸面 SAH(红色箭头)。B 图,可见蛛网膜下腔强化;C 图,Flair 显示双侧不对称白质高信号。图 D 和 E,右侧顶叶弥散抑制(绿色箭头):



F 图,SWI 可见皮层微出血(黄色箭头)。G 图,激素治疗后复查 MR 显示右侧顶叶白质高信号缓解:



该患者符合 CAA-RI 的诊断标准,给予静脉输注甲强龙,临床和影像学改善。

原始出处:Theodorou A1, Lachanis S2, Alexopoulos P2, et al. Teaching NeuroImages: Acute convexity subarachnoid hemorrhage: An underrecognized presentation of CAA-ri. Neurology. 2019 Jul 30;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000860, encodeId=7d2920008602a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jul 25 18:06:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460313, encodeId=d6311460313cf, content=<a href='/topic/show?id=de5015845be' target=_blank style='color:#2F92EE;'>#SAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15845, encryptionId=de5015845be, topicName=SAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9f06287396, createdName=zexyw03, createdTime=Fri Aug 30 18:06:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534004, encodeId=7c76153400415, content=<a href='/topic/show?id=238c3942eb' target=_blank style='color:#2F92EE;'>#CAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3942, encryptionId=238c3942eb, topicName=CAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad6312510186, createdName=huangdf, createdTime=Fri Aug 30 18:06:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2020-07-25 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000860, encodeId=7d2920008602a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jul 25 18:06:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460313, encodeId=d6311460313cf, content=<a href='/topic/show?id=de5015845be' target=_blank style='color:#2F92EE;'>#SAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15845, encryptionId=de5015845be, topicName=SAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9f06287396, createdName=zexyw03, createdTime=Fri Aug 30 18:06:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534004, encodeId=7c76153400415, content=<a href='/topic/show?id=238c3942eb' target=_blank style='color:#2F92EE;'>#CAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3942, encryptionId=238c3942eb, topicName=CAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad6312510186, createdName=huangdf, createdTime=Fri Aug 30 18:06:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-08-30 zexyw03
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000860, encodeId=7d2920008602a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jul 25 18:06:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460313, encodeId=d6311460313cf, content=<a href='/topic/show?id=de5015845be' target=_blank style='color:#2F92EE;'>#SAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15845, encryptionId=de5015845be, topicName=SAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9f06287396, createdName=zexyw03, createdTime=Fri Aug 30 18:06:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534004, encodeId=7c76153400415, content=<a href='/topic/show?id=238c3942eb' target=_blank style='color:#2F92EE;'>#CAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3942, encryptionId=238c3942eb, topicName=CAA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad6312510186, createdName=huangdf, createdTime=Fri Aug 30 18:06:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-08-30 huangdf

相关资讯

NCC:诱导性高血压治疗SAH后迟发性脑缺血

诱导高血压是治疗SAH后迟发性脑缺血(DCI)的常用治疗措施。这项治疗措施通过提高脑灌注压,从而维持或改善脑血流量(CBF)。尽管可能改善预后,但是DCI后诱导性高血压改善预后的有效性和安全性并不清楚。

Neurology:SAH 后早期脑损伤与早期播散去极化有关

动脉瘤破裂后,脑实质损害决定了患者的预后。初期的全面缺血会引起弥漫性全脑水肿(global cerebral edema,GCE)和不良预后。在介入前的 CT 扫描中,脑出血(ICH)周围往往环绕着局灶损害。早期或延迟局灶性损害更常见于被血液填充的脑沟和脑裂周围的皮质。在传统的病理文献中,这些损害被称为『局灶性贫血坏死(“focal anemic necroses)』,在 CT 上表现为明显的低密

Neurology:低剂量阿司匹林不增加颅内出血风险,反而降低SAH风险

低剂量阿司匹林广泛应用于缺血性血管事件的二级预防,甚至用于一级预防。随机对照试验或随机对照试验联合队列研究的meta分析把阿司匹林和颅内出血风险增加联系起来,发现二者未达到统计学意义或处于边缘状态。观察性研究的结果更是模棱两可,甚至有研究认为长期服用阿司匹林能够降低蛛网膜出血的风险。

Stroke:蛛网膜下腔出血后骨质疏松症与脑积水的关系

蛛网膜下腔出血(SAH)后蛛网膜颗粒的病理性阻塞可阻碍脑脊液向静脉窦外流并引起脑积水。由于骨骼和蛛网膜颗粒具有相同的胶原类型,研究者评估了SAH后骨密度和分流依赖性脑积水的可能关系。相关研究结果于近期发表在Stroke杂志。

Neurology:同时脑梗死和蛛网膜下腔出血是什么原因?

47岁,男性。既往抽烟和高血压病史。因为突发剧烈头痛就诊。

Stroke:诱导性高血压预防 SAH 后 脑梗死

动脉瘤蛛网膜下腔出血(SAH)的发病率为6-7/10万人-年,占所有卒中的5%。一半的患者年龄低于55岁,不良预后超过50%。24h 内幸存患者不良预后最重要的原因为迟发性脑缺血(DCI),DCI 通常发生在 SAH 后4-10天。截止到目前为止,L-型钙离子拮抗剂尼莫地平是唯一被证明能够预防 SAH 后 DCI 的措施。